|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT01858103 |
|
Date of registration:
|
15/05/2013 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
BMN 110 US Expanded Access Program
|
|
Scientific title:
|
A Multicenter, Open-label BMN 110 US Expanded Access Program (BMN 110 US EAP) to Provide BMN 110 to Patients Diagnosed With MPS IVA |
|
Date of first enrolment:
|
January 2009 |
|
Target sample size:
|
|
|
Recruitment status: |
Approved for marketing |
|
URL:
|
http://clinicaltrials.gov/show/NCT01858103 |
|
Study type:
|
Expanded Access |
|
Study design:
|
N/A
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Puerto Rico
|
United States
| | | | | | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Diagnosed with MPS IVA as confirmed by either N-acetylgalactosamine-6-sulfatase
(GALNS) enzymatic test (GALNS activity in affected range, beta-galactosidase and a
second lysosomal sulfatase activity within normal range) or molecular diagnostic test
(two mutations in GALNS identified that have previously been associated with an
enzyme defect).
- Willing and able to provide written, signed informed consent, or in the case of
patients under the age of 18, provide written assent (as required by the IRB) and
written informed consent by a legally authorized representative after the nature of
the program has been explained, and prior to any program assessments or evaluations.
- Sexually active patients must be willing to use an acceptable method of contraception
while participating in the program.
- Females of childbearing potential must have a negative pregnancy test at Baseline and
be willing to have additional pregnancy tests during the program.
- Willing and able to comply with all program procedures.
Exclusion Criteria:
- Pregnant or breastfeeding at Baseline or planning to become pregnant (self or
partner) at any time during the program. Patients who become pregnant during the
program will be discontinued from the program.
- Currently enrolled in an ongoing clinical study of BMN 110.
- Discontinued from a BMN 110 clinical study secondary to a safety-related event.
- Use of any investigational product (other than BMN 110 in a clinical study) or
investigational medical device within 30 days prior to Baseline, or requirement for
any investigational agent prior to completion of all scheduled program assessments.
- Not a current US resident or expecting to have travel plans outside the US during the
planned period of participation in the Expanded Access Program (EAP) that may
interfere with dosing regimen, scheduled program visits and safety monitoring.
- Any condition that, in the view of the Investigator or sponsor, places the patient at
high risk of poor treatment compliance or of not completing the EAP.
Age minimum:
N/A
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
MPS IVA
|
|
Mucopolysaccharidosis IVA
|
|
Morquio A Syndrome
|
|
Intervention(s)
|
|
Drug: BMN 110
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|